1. We have studied the effect of inhibiting the interaction of platelet-activating factor with its receptor by using two structurally different antagonists BN-52021 (1 mg/kg, intraperitoneally) and alprazolam (1 and 5 mg/kg, intraperitoneally) on the evolution of glomerular filtration and renal blood flow, in the experimental model of acute renal failure induced by the intramuscular injection of glycerol in rats.
INTRODUCTION
The glycerol model of acute renal failure (ARF) has been extensively examined. This model of myohaemoglobinuric ARF, characterized by oliguria and a marked diminution of glomerular filtration rate (GFR), is similar to that seen in some clinical settings, especially the ARF associated with extensive trauma [ 11. The pathophysiology of this model is not totally clear, but an important haemodynamic component seems to have been clearly demonstrated [2, 31. Numerous investigators have reported that acute reduction in renal plasma flow (FWF) is present early in the course of glycerol-induced ARF, and there is evidence that ischaemia is responsible for the decreased GFR [4-61.
Platelet-activating factor (PAF-acether, 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine) is an alkyl phosphoglyceride with numerous biological actions on renal function [7, 81. It has been reported that PAF-acether is produced by the kidney [7, 91 , and that it is synthesized and released by the glomerular mesangial cells [lo] . The infusion of PAF-acether causes reductions in GFR and renal blood flow (RBF) [ll, 121 . For all of these reasons, PAF-acether may be a mediator in the reduction of RBF and GFR observed in ARF. To assess this hypothesis we have studied the effect of inhibiting the interaction of PAF-acether with its receptor by using two structurally different specific antagonists of PAF-acether, BN-5202 1 [13, 141 and alprazolam [15] , on the changes in GFR, RF' F, RBF and electrolyte excretion in the experimental model of ARF induced by the intramuscular injection of glycerol. We have also measured the production of bioassayable PAF-acether by kidneys and glomeruli isolated from rats with and without ARF. Since it is well established that considerable amounts of fluid are sequestered in the area of glycerol injection [16] , and the effect of PAF-acether on vascular permeability is well known [17] , it seems possible that the protective effect of BN-52021 could be based on its influence on fluid trapping. Thus the effect of BN-52021 on blood volume changes after ARF induction has also been assessed.
METHODS

Clearance studies
Experiments were performed in male Wistar rats. The animals were anaesthetized with sodium pentobarbital (40 mg/kg) and placed on a heated animal board. Rectal temperature was monitored with a thermistor and was maintained at 37°C. Animals were surgically prepared for clearance studies by inserting PE-50 polyethylene catheters in the femoral artery and vein and in the bladder. The femoral artery was connected to a pressure transducer (Statham Instruments, Hato Rey, Puerto Rico) for the continuous recording of mean arterial pressure on a Dynograph polygraph (Beckmann Instruments, Schiller Park, IL, U.S.A.). Urine was collected from a bladder catheter into pre-weighed plastic vials containing 0.5 ml of water-stabilized mineral oil. An infusion of saline ( 154 mmol/l NaCl) containing [ meth~xy-'~~C]inulin and p-[3H]aminohippuric acid was started at a rate of 1.2 ml/h through the venous catheter to allow clearance determinations. After 30 min of equilibration, two 30 min urine collections were performed, with blood sampling (1 50 p l ) at the beginning and end of each clearance period. Packed cell volume was determined by the microcapillary method. ARF was induced by intramuscular injection (both lower limbs) of 50% (w/v) glycerol in water (10 ml/ kg body weight) and immediately eight rats received BN-52021 (1 mg/kg, intraperitoneally) and the other eight rats received the BN-5202 1 solvent dimethylsulphoxide (DMSO) [So% (w/v) in saline]. Six rats received 1 mg of alprazolam/kg body weight (intraperitoneally) and another six animals received 5 mg of alprazolam/kg body weight (intraperitoneally). In two groups of five rats each, BN-5202 1 (1 mg/kg body weight) or alprazolam ( 5 mg/kg body weight) was injected but these rats did not receive any glycerol. Then three consecutive 30 min clearance periods were observed.
Studies in metabolic cages
Experiments were performed in 20 male Wistar rats weighing about 250 g. The animals were placed into individual metabolic cages 4 days before induction of ARF, and urine free of food and faeces, was collected daily into graduated cylinders. ARF was induced as previously described. Then half of the rats were intraperitoneally injected with BN-5202 1 ( 1 .O mg/kg body weight), dissolved in 50% dimethylsulphoxide in distilled water, whereas the other half was intraperitoneally injected with 50% dimethylsulphoxide in distilled water (1 ml/kg body weight). Animals were replaced in the metabolic cages and urine was collected over 24 h periods for 3 days. Each day a blood sample (0.5 ml) was taken by cardiac puncture and replaced by saline (0.5 ml, intraperitoneally ).
Morphological studies
At the end of the clearance periods, in the ARF group and in the ARF group treated with BN-52021, kidneys were fixed by perfusion at mean arterial pressure with 1.25% glutaraldehyde in 0.1 mol/l sodium cacodylate buffer (pH 7.4, osmolality 300 mosmol/kg) followed by immersion in this fixative for 3 h. Sections were embedded in paraffin and stained with haematoxylineosin. Slides were reviewed blindly by two different pathologists and scored with a semi-quantitative scale evaluating the changes more frequently found in ARF. Higher scores represent more severe damage (the maximum score per tubule was 10) with points given for presence and extent of tubular epithelial cell flattening (1 point), brush-border loss (1 point), cell membrane bleb formation (1 to 2 points), interstitial oedema (1 point), cytoplasmic vacuolization ( 1 point), cell necrosis (1 or 2 points) and tubular lumen obstruction (1 or 2 points).
Blood volume studies
Changes in blood volume after ARF induction were monitored by determining the distribution space of "Crlabelled homologous erythrocytes in a different group of BN-52021-and DMSO-treated Wistar rats. Erythrocytes were marked as described by Eisemberg [18] . For this purpose, early in the morning 0.5 ml of blood was taken from each rat by jugular puncture, using citric acid-D-glucose as anticoagulant. Erythrocytes were obtained by centrifugation and incubated for 30 min at 37°C in phosphate-buffered saline containing 20 pCi of 51Cr (Amersham). Then erythrocytes were washed four times with phosphate-buffered saline to remove free isotope and the radioactivity of a sample of cells was measured in a y-counter. A suspension of erythrocytes containing a known amount of radioactivity was then injected in the rat, and after allowing 15 min for adequate mixing, blood samples (150 pl) were taken before and several times after glycerol injection. Blood radioactivity was determined in a y-counter and erythrocyte distribution space was calculated by using standard formulae.
Incubation of isolated glomeruli and PAF-acether extraction
Experiments were performed in 14 animals. In five of them, glycerol and DMSO (the BN-52021 solvent) were injected as described above. Five rats received glycerol and BN-5202 1, whereas four received only intramuscular saline and DMSO. After 1 h, kidneys were removed and glomeruli were isolated by a sieving technique, as previously described [ 191. Freshly isolated glomeruli were placed in tubes containing 1.5 ml of Tris-glucose buffer (20 mmol/l Tris, 130 mmol/l NaCl, 10 mmol/l KCl, 2.5 mmol/l CaCI,, 10 mmol/l sodium acetate and 5 mmol/l glucose, pH 7.45), containing phenylmethane sulphonyl fluoride (final concentration mol/l) to prevent rapid degradation of PAF-acether [20] . Tubes were incubated at room temperature for 30 min and glomeruli were separated by centrifugation at 3000 rev./min for 3 min. The supernatant was mixed with 5 ml of cold methanol acidified with acetic acid (49: 1, v/v) and PAF-acether was extracted. Glomeruli were mixed with 5 ml of cold acidified methanol, sonicated for 30 s and slowly stirred for 30 min. Then tubes were centrifuged and the pellet was again mixed with 5 ml of cold methanol, stirred for 30 min and centrifuged. Both methanol phases were pooled. PAF-acether was extracted from the methanol phase as previously described [2 11 . Briefly, chloroform and water were added to the methanol in proportions of 1 :0.9: 1 (by vol.) and gently stirred. After phase formation by centrifugation, the chloroform phase was removed and new chloroform was added to the methanol/water in the same proportions as above. The process was repeated and both chloroform extracts were pooled and dried under N,. PAF-acether extraction was performed with silica cartridges (Sep-Pak, Waters, Milford, MA, U.S.A.) [2 11 . Cartridges were rinsed with 5 ml of chloroform and then the sample was resuspended in 5 ml of chloroform acidified with HCl to pH 3-4 and applied to the cartridge. The column was eluted sequentially with 5 ml of chloroform/methanol (3: 1, v/v), 5 ml of chloroform/methanol (3:2, v/v) 5 ml of chloroform/methanol (1 :3, v/v and 5 ml of methanol/water (3:1, v/v). The last fraction containing PAF-acether was collected and dried under N,. In preliminary studies we observed that [3H]thromboxane B, (Amersham) completely eluted from the cartridge with the two solvents, and that none of this compound appeared in the fractions in which FAF-acether was recovered. PAF-acether recovery varied between 70 and 80%.
Renal PAF-acether production
This study was performed in 49 animals. In 33 of them, ARF was produced as previously described. Ten of these animals received BN-52021 (1 mg/kg body weight). Eleven animals received alprazolam ( 5 mg/kg body weight). A group of 16 rats who had undergone a sham operation served as controls. After 1 h of ARF induction, a sample of renal venous blood (1 ml) was taken by puncture of the left renal vein and was immediately placed in 7 ml of ice-cold acidified methanol. Tubes were vigorously mixed and slowly stirred for 30 min. Then tubes were centrifuged and the pellet was again mixed with 5 ml of cold methanol, stirred for 30 min and centrifuged. Both methanol phases were pooled. PAF-acether was extracted from the methanol phase as above.
Bioassayable PAF-acether activity PAF-acether activity was determined by the release of 5-['H]hydroxytryptamine from preloaded rabbit platelets in the presence of indomethacin (lo-', mol/l) as previously described [21] . A standard curve of the response to PAF-acether was produced with concentrations between 3.6 x lo-" and 3.8 x mol/l. The amount of 5-['H]hydroxytryptamine released by the lower standard was significantly higher than the non-specific release. The amount of PAF-acether activity was quantified by interpolating the values of 5-[3H]hydroxytryptamine release from platelets in presence of 100 pl of the sample in triplicate. Only the values corresponding to the linear portion of the curve (between 3.8 x lo-" and 7.7 x 10-'" mol/l) were used for quantification.
Plasma and urinary determinations
Sodium, potassium and chloride in plasma and urine were determined by selective ion electrodes (Astra W, Beckman, Fullerton, CA, U.S.A.). 3H and 14C radioactivities were measured by using a two-channel liquid scintillation counter which corrects cross-talk between isotopes. Creatinine was measured in plasma and urine by an automated method (Astra W, Beckmann) and creatinine clearance was calculated by using standard formulae.
Statistical methods
Data are shown as m e a n s k s~~. Differences between means were analysed by paired or unpaired Student's t-test or analysis of variance as appropriate. P values > 0.05 were considered to be not significant.
RESULTS
Clearance studies
After glycerol injection, rats that received only DMSO showed a progressive reduction in inulin clearance (Fig.  1 ) which fell by 77% in the first 30 min, whereas only a 27% reduction was seen in the rats treated with BN-52021 and a 38% reduction was seen in the rats treated with alprazolam ( 5 mg/kg). The results for p-aminohippuric acid clearance were similar (Fig. 2) . The effect of BN-52021 seems to disappear after 90 min of injection, but not that of alprazolam. In addition, fractional sodium excretion was lower in treated than in untreated rats (Table 1) . Urine flow was also higher in the rats treated with BN-52021 or alprazolam than in those that were not treated. BN-52021 or alprazolam, per se, did not induce any significant changes in GFR, RPF, RBF or mean arterial pressure (Table 2) .
Metabolic cage studies
The results are given in Table 3 . It can be seen that urinary flow was higher in the animals treated with BN-52021 than in the non-treated group, although the differences were not statistically significant due to the high variability of the data. Urinary creatinine excretion was higher in the BN-52021-treated than in the untreated groups in the first 2 days after ARF induction, but no differences were observed on the third day. In addition, creatinine clearance was higher in BN-5202 1-treated than in untreated rats. The opposite was observed with plasma creatinine in that it increased more in the untreated than in the BN-5202 1-treated group. Sodium and chloride excretion was higher in rats treated with PAF-acether antagonist than in the untreated rats.
Morphological studies
Kidneys from rats with ARF showed the typical tubular lesions already reported for this experimental model [22] . Briefly, in the superficial cortical area there was an extensive loss of the proximal tubular epithelial cell brush-border, with a high percentage of cystolic vacuolization. Between 20 and 80% of the tubular lumens were filled with a dye identified as myoglobin-haemoglobin. Proximal tubular lesion vaned between moderate (2 points) and severe (8 points). Distal tubular lesion was more moderate, and only a small proportion ( < 10%) showed dilated tubular lumens and flattened tubular epithelium. In the juxtamedular cortical area, similar lesions but less variable in intensity (3-4 points) were observed, with 30-60% luminal obstruction. The outer medulla was relatively well conserved, but with some degree of cytoplasmic vacuolization. Luminal obstruction was observed in about 30% of the tubules. The papilla was well conserved and lumen was obstructed only in 5-10% of the tubules. Interstitial oedema was only rarely observed. The degree of histological damage, measured as described above, was similar in BN-52021-treated and untreated rats (ARF 4.76 f 0.45 points, ARF plus BN-52021 3.65 f 0.43 points, not significant).
Blood volume studies
The distribution spaces of 'Cr-labelled erythrocytes in both experimental groups are shown in Fig. 3 . No differences were observed between BN-5202 1-treated and untreated rats.
Glomerular PAF-acether production
PAF-acether production by glomeruli isolated from rats with ARF and normal rats is shown in Table 4 . The amount of PAF-acether in the glomeruli from normal rats was below the limits of detection of the assay, whereas that in the glomeruli from rats with ARF was detectable. The amount of PAF present in the supernatant from rats with ARF was significantly higher than that in normal rats. No difference was observed between glomeruli from rats with ARF, treated with BN-52021 or untreated.
Renal PAF-acether production
As shown in Fig. 4 , in normal rats PAF-acether concentration in the renal vein was lower than in the renal artery. However, kidneys from rats with glycerol-induced ARF showed a higher PAF-acether concentration in the renal vein than in the renal artery. No significant difference was observed between BN-5202 1-treated and untreated rats with A R E
DISCUSSION
These results demonstrate that a single injection of BN-52021 (1 mg/kg) or alprazolam ( 5 mg/kg), two structurally different PAF-acether antagonists that specifically block PAF-acether-receptor interaction in a competitive manner [ 13-1 51, protects effectively against the sharp decrease in GFR and RBF induced by intramuscular injection of glycerol in rats. As BN-5202 1 and alprazolam have been demonstrated to be specific and powerful blockers of the binding of PAF-acether to its receptor demonstrated that PAF-acether mediates endotoxininduced ARF in rats [23] . Several pieces of evidence indicate that the kidney can produce PAF-acether: (a) it is released by isolated kidneys [9], isolated glomeruli or cultured mesangial cells after appropriate stimuli [lo, 211, (b) PAF-acether can be recovered in urine [24] , and (c) PAFacether can be detected in plasma from normal man and rats, but not from anephric subjects and rats [25] . The mechanism of PAF-acether-mediated reduction of RPF and GFR is not completely understood, but it seems to be multifactorial. First, PAF-acether is able to constrict vascular smooth muscle [8, 171, thus increasing renal vascular resistance. Second, PAF-acether can induce mesangial cell contraction [26-281, which can also decrease RPF by increasing resistance to blood flow, and GFR by reducing the ultrafiltration coefficient. It is interesting to note that treatment with BN-5202 1 protects against PAF-acetherinduced mesangial cell contraction [29] . The protection induced by BN-52021 or alprazolam against glycerol-induced AFW does not seem to be based on differences in PAF-acether synthesis by the kidney, but on blocking the binding of PAF-acether to its renal receptors, because kidneys and glomeruli from treated and untreated rats released similar amounts of PAFacether.
Since it is well established that considerable amounts of fluid are sequestered in the glycerol injection zone, it seems possible that the protective effect of BN-52021 could be based on its influence on fluid trapping, because the effect of PAF-acether on vascular permeability is well known. However, the SICr-labelled erythrocyte distribution space results obtained suggest that the protective effect of BN-52021 is not based on differences in fluid trapping. The decrease in blood volume after glycerol injection is not reflected in the distribution space of slCr-labelled erythrocytes because of the simultaneous decrease in blood volume and erythrocyte lysis, as previously described [16] . Thus, a significant amount of "Cr is released from lysed erythrocytes and trapped in the limb oedema.
The functional protection afforded by BN-52021 against AFW is not reflected by the degree of histological damage. Several authors have reported the imperfect correlation between the severity of ARF and the histological appearance of the kidney, both in man [30, 31] and in experimental models in the rat [32] . Thus, AFW seems to be a multifactorial phenomenon in which decreases in GFR and RBF and tubular cell necrosis are not directly related, and PAF-acether could play a major role in one of them but not in the other. In this connection, it should be noted that receptors for PAF-acether have been reported in glomeruli but not in proximal tubules [ 141.
In conclusion, pretreatment with BN-52021 or alprazolam, specific blockers of PAF-acether receptors, significantly ameliorates renal function in rats in which ARF has been induced by glycerol injection. This protection does not correlate with histological changes and it does not seem to be based on differences in fluid trapping in the injection zone or on differences in PAF-acether release by the glomeruli. These results, together with the increased PAF-acether content in glomeruli and the increased release of PAF from the kidneys of these animals, provide some evidence of a role for PAF-acether in the physiopathology of renal failure in this model of experimental ARF, at least in the first stages.
